Dulaglutide and insulin microsecretion in people with type 1 diabetes (DIAMOND-GLP-1): A randomized double-blind placebo-controlled trial - 10/03/23

Charles Thivolet ^{a, ⁎}

^a Centre du diabète DIAB-eCARE, Hospices Civils de Lyon, Université Claude Bernard Lyon 1, Lyon France 

^⁎Corresponding author.

Etienne Larger ^b

^b Department of Diabetology, Cochin Hospital AP-HP, University of Paris, Paris, France 

Bertrand Cariou ^c

^c Nantes Université, CHU Nantes, CNRS, INSERM, l'institut du thorax, Nantes F-44000, France 

Eric Renard ^d

^d Department of Endocrinology, Diabetes and Nutrition, Montpellier University Hospital, University of Montpellier, Montpellier, France 

Hélène Hanaire ^e

^e Department of Diabetology, Metabolic diseases and Nutrition, CHU Toulouse, University of Toulouse, Toulouse, France 

Pierre-Yves Benhamou ^f

^f Department of Endocrinology, Grenoble University Hospital, Grenoble Alpes University, INSERM U1055, LBFA, Grenoble, France 

Bruno Guerci ^g

^g Department of Endocrinology, Diabetology and Nutrition, CHRU of Nancy, Brabois Hospital, and ILCV Lorraine University, Vandoeuvre-les-Nancy, France 

Émilie Mathiotte ^h

^h Department of Clinical Research, pole IMER Hospices Civils de Lyon, Lyon, France 

Karim Chikh ⁱ

ⁱ Department of biochemistry and molecular biology, Lyon-Sud Hospital, Hospices Civils de Lyon, Lyon, France, Université Claude-Bernard Lyon 1, Oullins, France 

Le texte complet de cet article est disponible en PDF.